Diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type B conjugate vaccine (GlaxoSmithKline)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDiphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type B conjugate vaccine (GlaxoSmithKline)
Drug Alias NameDiphtheria, tetanus, pertussis (whole cell), hepatitis B (rDNA) and Haemophilus influenzae type B conjugate vaccine (absorbed)白喉，破伤风，百日咳，乙型肝炎和B型流感嗜血杆菌结合疫苗Quintanrix
ClassificationVaccines > Vaccine type > Combination vaccineVaccines > Biological material > Toxoid vaccineVaccines > Development/production technology > Conjugated vaccine +[6] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRotavirus InfectionsHepatitis BStreptococcal Infections +[9] 
Global Approved IndicationsHepatitis BTetanusDiphtheria +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2005/02/17
Country/TerritoryThailandPhilippinesBangladesh +[7] 
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcGlaxosmithkline Biologicals SA
Active IndicationsN/A
Inactive IndicationsRotavirus InfectionsHepatitis BStreptococcal Infections +[9] 

Other Information

ATC CodeJ07CA10
Related LinksN/A